RU2517693C2 - Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов - Google Patents

Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов Download PDF

Info

Publication number
RU2517693C2
RU2517693C2 RU2009138600/04A RU2009138600A RU2517693C2 RU 2517693 C2 RU2517693 C2 RU 2517693C2 RU 2009138600/04 A RU2009138600/04 A RU 2009138600/04A RU 2009138600 A RU2009138600 A RU 2009138600A RU 2517693 C2 RU2517693 C2 RU 2517693C2
Authority
RU
Russia
Prior art keywords
diazabicyclo
ylcarbonyl
nonane
octane
compounds
Prior art date
Application number
RU2009138600/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2009138600A (ru
Inventor
Анатолий Мазуров
Лань Мяо
Юнь-дэ СЯО
Филип С. Хэммонд
Крэйг Х. Миллер
Сринивиса Рао Акиредди
В. Сриниваса МЕРТИ
Реджина С. УИТАКЕР
Скотт Р. Брейнинг
Мэтт С. МЕЛВИН
Original Assignee
Таргасепт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Таргасепт, Инк. filed Critical Таргасепт, Инк.
Publication of RU2009138600A publication Critical patent/RU2009138600A/ru
Application granted granted Critical
Publication of RU2517693C2 publication Critical patent/RU2517693C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2009138600/04A 2006-11-02 2007-11-01 Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов RU2517693C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
US60/856,079 2006-11-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009120674/04A Division RU2448969C2 (ru) 2006-11-02 2007-11-01 Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов и фармацевтическая композиция и способы лечения с их использованием

Publications (2)

Publication Number Publication Date
RU2009138600A RU2009138600A (ru) 2011-04-27
RU2517693C2 true RU2517693C2 (ru) 2014-05-27

Family

ID=39233054

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009138600/04A RU2517693C2 (ru) 2006-11-02 2007-11-01 Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов
RU2009120674/04A RU2448969C2 (ru) 2006-11-02 2007-11-01 Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов и фармацевтическая композиция и способы лечения с их использованием

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2009120674/04A RU2448969C2 (ru) 2006-11-02 2007-11-01 Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов и фармацевтическая композиция и способы лечения с их использованием

Country Status (32)

Country Link
US (6) US8114889B2 (enExample)
EP (2) EP2094703B1 (enExample)
JP (2) JP5539723B2 (enExample)
KR (2) KR20100124356A (enExample)
CN (4) CN102942569B (enExample)
AR (2) AR063451A1 (enExample)
AT (2) ATE509022T1 (enExample)
AU (2) AU2007317433B2 (enExample)
BR (2) BRPI0717930A2 (enExample)
CA (1) CA2663925C (enExample)
CL (1) CL2007003155A1 (enExample)
CO (1) CO6180435A2 (enExample)
CY (1) CY1112374T1 (enExample)
DK (1) DK2094703T3 (enExample)
ES (2) ES2395157T3 (enExample)
HR (1) HRP20110570T1 (enExample)
IL (2) IL197618A (enExample)
MX (1) MX2009004801A (enExample)
MY (2) MY156730A (enExample)
NO (1) NO20091251L (enExample)
NZ (2) NZ587847A (enExample)
PE (2) PE20081441A1 (enExample)
PL (1) PL2094703T3 (enExample)
PT (1) PT2094703E (enExample)
RS (1) RS51834B (enExample)
RU (2) RU2517693C2 (enExample)
SA (1) SA07280584B1 (enExample)
SI (1) SI2094703T1 (enExample)
TW (3) TWI405763B (enExample)
UA (2) UA106718C2 (enExample)
UY (1) UY30686A1 (enExample)
WO (1) WO2008057938A1 (enExample)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2707751C1 (ru) * 2017-03-20 2019-11-29 Форма Терапьютикс, Инк. Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr)
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
RU2725138C2 (ru) * 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US10882857B2 (en) 2017-03-16 2021-01-05 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
US11098048B2 (en) 2014-03-26 2021-08-24 Hoffmann-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US12161634B2 (en) 2019-09-19 2024-12-10 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20110071180A1 (en) * 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
JP2012502039A (ja) * 2008-09-05 2012-01-26 ターガセプト，インコーポレイテッド ジアザビシクロオクタンのアミド及びその用途
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
JP5536227B2 (ja) 2009-11-18 2014-07-02 スヴェン・ライフ・サイエンシズ・リミテッド α４β２ニコチン性アセチルコリン受容体リガンドとしての二環式化合物
ES2552932T3 (es) 2009-12-29 2015-12-03 Suven Life Sciences Limited Ligandos del receptor nicotínico neuronal de la acetilcolina alfa4beta2
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124014C1 (ru) * 1993-12-29 1998-12-27 Пфайзер Инк. Диазабициклические соединения и содержащая их фармацевтическая композиция
RU2172739C2 (ru) * 1996-02-23 2001-08-27 Астра Актиеболаг Азабициклические сложные эфиры карбаминовых кислот, способы их получения, фармацевтическая композиция и промежуточные соединения
WO2004016616A1 (en) * 2002-08-14 2004-02-26 Astrazeneca Ab Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
WO2004076453A1 (en) * 2003-02-27 2004-09-10 Neurosearch A/S Novel diazabicyclic aryl derivatives
US20040186107A1 (en) * 2000-04-27 2004-09-23 Schrimpf Michael R. Diazabicyclic central nervous system active agents
US20050101602A1 (en) * 2003-09-19 2005-05-12 Anwer Basha Substituted diazabicycloalkane derivatives

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1406900B1 (en) 2001-07-06 2006-10-04 Neurosearch A/S Novel compounds, their preparation and use
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
CA2574307A1 (en) * 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
CN101193635A (zh) 2005-05-13 2008-06-04 莱西肯医药有限公司 多环化合物及其使用方法
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124014C1 (ru) * 1993-12-29 1998-12-27 Пфайзер Инк. Диазабициклические соединения и содержащая их фармацевтическая композиция
RU2172739C2 (ru) * 1996-02-23 2001-08-27 Астра Актиеболаг Азабициклические сложные эфиры карбаминовых кислот, способы их получения, фармацевтическая композиция и промежуточные соединения
US20040186107A1 (en) * 2000-04-27 2004-09-23 Schrimpf Michael R. Diazabicyclic central nervous system active agents
WO2004016616A1 (en) * 2002-08-14 2004-02-26 Astrazeneca Ab Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
WO2004076453A1 (en) * 2003-02-27 2004-09-10 Neurosearch A/S Novel diazabicyclic aryl derivatives
US20050101602A1 (en) * 2003-09-19 2005-05-12 Anwer Basha Substituted diazabicycloalkane derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
. *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US11098048B2 (en) 2014-03-26 2021-08-24 Hoffmann-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US11352330B2 (en) 2015-09-04 2022-06-07 Hoffmann-La Roche Inc. Phenoxymethyl derivatives
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
RU2725138C2 (ru) * 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
RU2724899C2 (ru) * 2015-09-24 2020-06-26 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
US10889588B2 (en) 2015-09-24 2021-01-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
US11673888B2 (en) 2017-03-16 2023-06-13 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10882857B2 (en) 2017-03-16 2021-01-05 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US11649242B2 (en) 2017-03-20 2023-05-16 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
RU2707751C1 (ru) * 2017-03-20 2019-11-29 Форма Терапьютикс, Инк. Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr)
US12071440B2 (en) 2017-03-20 2024-08-27 Novo Nordisk Health Care Ag Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
US10836771B2 (en) 2017-03-20 2020-11-17 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
RU2736217C2 (ru) * 2017-03-20 2020-11-12 Форма Терапьютикс, Инк. Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr)
US11396513B2 (en) 2017-03-20 2022-07-26 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
US11071725B2 (en) 2018-09-19 2021-07-27 Forma Therapeutics, Inc. Activating pyruvate kinase R
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US11844787B2 (en) 2018-09-19 2023-12-19 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US11980611B2 (en) 2018-09-19 2024-05-14 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US12122778B2 (en) 2018-09-19 2024-10-22 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US12161634B2 (en) 2019-09-19 2024-12-10 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Also Published As

Publication number Publication date
MY145602A (en) 2012-03-15
MY156730A (en) 2016-03-15
AR079840A2 (es) 2012-02-22
UA106718C2 (uk) 2014-10-10
PE20110671A1 (es) 2011-10-20
EP2284171A1 (en) 2011-02-16
RS51834B (sr) 2012-02-29
US20100081683A1 (en) 2010-04-01
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
CA2663925A1 (en) 2008-05-15
CN102020646B (zh) 2013-11-13
CN102942569A (zh) 2013-02-27
CN102942569B (zh) 2015-10-28
JP5739398B2 (ja) 2015-06-24
US20130005789A1 (en) 2013-01-03
BRPI0717930A2 (pt) 2011-05-10
EP2094703B1 (en) 2011-05-11
CL2007003155A1 (es) 2008-05-16
US20100173932A1 (en) 2010-07-08
CN101528745B (zh) 2011-09-14
RU2009120674A (ru) 2010-12-10
AR063451A1 (es) 2009-01-28
PE20081441A1 (es) 2008-10-30
IL209026A (en) 2014-03-31
TWI405763B (zh) 2013-08-21
JP2013056919A (ja) 2013-03-28
EP2094703A1 (en) 2009-09-02
HK1149751A1 (en) 2011-10-14
IL209026A0 (en) 2011-01-31
IL197618A (en) 2013-09-30
PT2094703E (pt) 2011-07-22
US8859609B2 (en) 2014-10-14
AU2007317433B2 (en) 2012-05-10
ES2395212T3 (es) 2013-02-11
DK2094703T3 (da) 2011-08-29
PL2094703T3 (pl) 2011-10-31
CA2663925C (en) 2015-04-21
NO20091251L (no) 2009-05-28
US8114889B2 (en) 2012-02-14
UA98944C2 (ru) 2012-07-10
CN102020646A (zh) 2011-04-20
WO2008057938A1 (en) 2008-05-15
RU2009138600A (ru) 2011-04-27
AU2010219323A1 (en) 2010-09-30
KR20090074051A (ko) 2009-07-03
MX2009004801A (es) 2009-07-31
RU2448969C2 (ru) 2012-04-27
KR101415705B1 (ko) 2014-07-04
ATE509022T1 (de) 2011-05-15
TW201305176A (zh) 2013-02-01
BRPI0722387A2 (pt) 2023-02-23
CY1112374T1 (el) 2015-12-09
TWI454262B (zh) 2014-10-01
EP2284171B1 (en) 2012-02-15
US9580434B2 (en) 2017-02-28
ES2395157T3 (es) 2013-02-08
SA07280584B1 (ar) 2010-11-02
AU2007317433A1 (en) 2008-05-15
US20160039833A1 (en) 2016-02-11
JP5539723B2 (ja) 2014-07-02
TW200826935A (en) 2008-07-01
US8268860B2 (en) 2012-09-18
TWI404532B (zh) 2013-08-11
US8921410B2 (en) 2014-12-30
CN102838605B (zh) 2017-04-26
US20120289572A1 (en) 2012-11-15
HK1133260A1 (en) 2010-03-19
CO6180435A2 (es) 2010-07-19
IL197618A0 (en) 2009-12-24
SI2094703T1 (sl) 2011-07-29
HRP20110570T1 (hr) 2011-09-30
ATE545646T1 (de) 2012-03-15
CN102838605A (zh) 2012-12-26
UY30686A1 (es) 2009-08-03
KR20100124356A (ko) 2010-11-26
NZ587847A (en) 2011-09-30
US20150080576A1 (en) 2015-03-19
TW201114424A (en) 2011-05-01
JP2010509230A (ja) 2010-03-25
NZ575557A (en) 2011-01-28

Similar Documents

Publication Publication Date Title
RU2448969C2 (ru) Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов и фармацевтическая композиция и способы лечения с их использованием
HK1149751B (en) Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types
HK1133260B (en) Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
AU2012205208A1 (en) Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151102